EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Effect of hydroxyurea on G gamma chain fetal hemoglobin synthesis by sickle-cell disease patients



Effect of hydroxyurea on G gamma chain fetal hemoglobin synthesis by sickle-cell disease patients



Brazilian Journal of Medical and Biological Research 36(10): 1289-1292



Hydroxyurea is used for sickle-cell disease patients in order to increase fetal hemoglobin synthesis and consequently decrease the severity of pain episodes. Fetal hemoglobin, which is formed by gamma-globin chains A and G, is present in a constant composition throughout fetal development: about 75% of Ggamma and 25% of Agamma. In contrast, adult red cells contain about 40% of Ggamma and 60% of Agamma. In the present study, we analyzed the effect of hydroxyurea induction on the gamma chain composition of fetal hemoglobin in 31 sickle-cell disease patients treated with hydroxyurea. The control group was composed of 30 sickle-cell disease patients not treated with hydroxyurea in clinical steady state. The patients were older than 13 years and were not matched for age. All patients were seen at Hemocentro/UNICAMP and Boldrini Infantile Center, Campinas, SP, Brazil. The levels of total hemoglobin were significantly higher in patients treated with hydroxyurea (mean +/- SD, 9.6+/-2.16 g/dl) than in untreated patients (8.07+/-0.91 g/dl). Fetal hemoglobin levels were also higher in treated patients (14.16+/-8.31%) than in untreated patients (8.8+/-4.09%), as was the Ggamma/Agamma ratio (1.45+/-0.78 vs 0.98+/-0.4, P < 0.005). The increase in the Ggamma/Agamma ratio in patients treated with hydroxyurea suggests the prevalence of a pattern of fetal hemoglobin synthesis, whereas patients not treated with hydroxyurea maintain the adult pattern of fetal hemoglobin synthesis. Because no correlation was observed between the Ggamma/Agamma ratio and total hemoglobin or fetal hemoglobin levels, the increase in Ggamma chain synthesis may not imply a higher production of hemoglobin.

(PDF emailed within 1 workday: $29.90)

Accession: 011997593

Download citation: RISBibTeXText

PMID: 14502358



Related references

Hydroxyurea induction of fetal hemoglobin synthesis in sickle-cell disease. Seminars in Oncology 19(3 Suppl 9): 61-66, 1992

Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease. Blood 91(12): 4472-4479, 1998

Hydroxyurea frequently induces fetal hemoglobin synthesis in sickle cell patients after a lag period. Clinical Research 37(2): 386A, 1989

Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients. Hemoglobin 35(1): 13-21, 2011

Relationship of burst-forming-unit-erythroid progenitors and their DNA-synthesis stage to fetal hemoglobin levels in hydroxyurea-treated patients with sickle cell anemia. American Journal of Hematology 46(4): 259-263, 1994

Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. New England Journal of Medicine 328(2): 73-80, 1993

Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease. American Journal of Hematology 72(2): 121-126, 2003

Induction of fetal hemoglobin in sickle cell patients by hydroxyurea: the N.I.H. experience. Progress in Clinical and Biological Research 316b: 281-293, 1989

Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood 89(3): 1078-1088, 1997

Effects of transfusions on the fetal hemoglobin response to Hydroxyurea and/or butyrate in sickle cell disease. Blood 98(11 Part 1): 492a, November 16, 2001

Enhanced inhibition of polymerization of sickle cell hemoglobin in the presence of recombinant mutants of human fetal hemoglobin with substitutions at position 43 in the gamma-chain. Biochemistry 44(36): 12188-12195, 2005

Increasing fetal hemoglobin in sickle cell disease: comparisons of 5-azacytidine (subcutaneous or oral) with hydroxyurea. Transactions of the Association of American Physicians 97: 140-145, 1984

A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease. Expert Review of Hematology 8(5): 669-679, 2016

Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea. Plos One 8(2): E55709-E55709, 2013

Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood 69(1): 109-116, 1987